# Base Editing Hematopoietic Stem Cell and T Cell Gene Therapy for CD40L-HyperIgM Syndrome: Single Patient Study

> **NCT06959771** · PHASE1,PHASE2 · RECRUITING · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 1 (estimated)

## Conditions studied

- CD40L-HyperIgM Syndrome

## Interventions

- **BIOLOGICAL:** Base-edited hematopoietic stem and progenitor cells
- **DRUG:** Alemtuzumab
- **DRUG:** Sirolimus
- **DRUG:** Palifermin
- **DRUG:** Busulfan
- **BIOLOGICAL:** Base-edited T lymphocyte cells

## Key facts

- **NCT ID:** NCT06959771
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-16
- **Primary completion:** 2027-10-28
- **Final completion:** 2027-10-28
- **Target enrollment:** 1 (ESTIMATED)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06959771

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06959771, "Base Editing Hematopoietic Stem Cell and T Cell Gene Therapy for CD40L-HyperIgM Syndrome: Single Patient Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06959771. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*